Researchers at Tel Aviv University have discovered that a type of white blood cell (eosinophils) can be utilized to fight cancer. They have a double effect, producing destructive proteins, while at the same time summoning the immune system’s cancer-fighting T-cells. … Continue reading →

This article describes the latest progress of Israel’s Immunai (see here previously) which is mapping the immune system to help develop new life-saving treatments. It acquired US-based Dropprint Genomics and has launched into development of cancer and autoimmune disease therapies. … Continue reading →

The UK National Health Service (NHS) is to trial the blood test from Israel’s OncoHost (see here previously) that predicts how well cancer patients will respond to immunotherapy treatment. Trials will focus on patients with advanced melanoma or non-small cell … Continue reading →

The Phase 1 / 2 trial of DSP107 from Israel’s KAHR Medical (see here previously) has commenced and will now be expanded to include blood cancer patients in addition to solid tumors. KAHR has received an additional investment of $5 … Continue reading →

Israel’s NeoTX Therapeutics (see here Mar 2020) has had FDA approval to begin Phase 2a human trials of its Naptumomab Estafenatox (NAP) treatment for non-small cell lung cancer. NAP binds bacteria to the tumor while activating tumor specific immune cells. … Continue reading →

Israel’s MyBiotics (see here previously) is to partner Hadasit – the technology transfer arm of Hadassah Medical Center, to identify gut microbiome-based cancer therapies. They will study up to 100 melanoma patients treated with PD-1/PD-L1 checkpoint inhibitor immunotherapies. https://www.timesofisrael.com/mybiotics-hadassah-to-study-impact-of-microbiome-on-cancer-therapies/

Scientists at Israel’s Weizmann Institute, working with others in the Netherlands and Norway, have discovered that melanoma cells can “frameshift” to grow whilst avoiding the immune system.  The process, however, generates new peptides (short proteins) that scientists can now target … Continue reading →

Israel’s Oncohost (reported here previously) presented the results of its latest proteomic (proteins) cancer study to the Society for Immunotherapy of Cancer’s (SITC). Oncohost’s PROphet host response profiling platform can predict the best therapy to use for specific cancer patients. … Continue reading →

Scientists at Israel’s Technion Institute have uncovered the atomic structure of Antimicrobial peptides (AMPs) in the immune system. It could lead to the design of similar artificial materials for technological and medical applications such as treating infections and even killing … Continue reading →